Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field

Global agreement for oral anti-viral comes just months after company signed separate similar tie-up for a Covid mRNA vaccine also in development Key Takeaways Everest has signed a global licensing deal for an anti-viral Covid treatment being developed by Singapore’s Experimental Drug Development Centre Similar oral anti-viral treatments have been developed by Pfizer and Merck, and are growing in popularity due to their ease of use By Richard Barbarossa Why settle for a single drug to treat Covid-19 when you can hedge your bets with two? That appears to be…

Read More »

New Horizon Health Gets Booster with New Product Approval

Company says its UU Tube used to self-screen for stomach cancer has been approved by China’s health regulator Key takeaways: New Horizon Health says its first-of-its-kind UU Tube self-screening product for stomach cancer has been approved for sale in China Company is already frothily valued compared with peers, though sales from new device could bring that down to healthier levels By Tina Yip Think back to last February when a hot Hong Kong biotech IPO wowed investors with a story of big riches from its early colorectal cancer screening kits.…

Read More »

Connect Biopharma’s Latest Dermatitis Drug Update Fails to Pump Up Shares

Company’s stock sank after it released data on Phase 2b trials for its atopic dermatitis drug, a potential competitor to Regeneron-Sanofi blockbuster Dupixent Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year Connect Biopharma shares, which more than halved after its November release of initial Phase 2 clinical trial data, fell further after latest update By Mia Shanley China’s Connect Biopharma Holdings Ltd. (CNTB.US) is just itching to bring in its first-ever revenue with…

Read More »

PW Medtech’s Buying Spree: Diversification or Insider Story?

The manufacturer of medical infusion devices has recently made two interesting acquisitions Key takeaways: After buying a related peer in November, PW Medtech acquired a human tissue regeneration and repair product developer last week at a high premium The company’s performance has been affected by the pandemic, and it may hope the new acquisitions will lower such risk through diversification By Jony Ho Medical device maker PW Medtech Group Ltd. (1358.HK) has struggled lately, dragged down by pandemic-related disruptions. Perhaps seeking to lower that risk, the company has made two…

Read More »

Zepp Health Stuck in Rut as Global Chip Shortage, Covid Weigh

Smart wearables maker cuts fourth-quarter revenue guidance, but expects to stay profitable, as competition intensifies Key takeaways: Zepp Health has cut its fourth-quarter revenue guidance, sending its shares to near all-time lows, as its shipments fall due to overreliance on Xiaomi relationship Global chip shortage and fresh Covid restrictions are also weighing on company as it tries to gain share in the crowded global smartwatch space By Mia Shanley Smart wearable device maker Zepp Health’s (ZEPP.US) efforts to carve out a niche in the crowded global smartwatch space are being…

Read More »

CStone Revs Up for Big Growth With New Drug Approval

Company says China has approved its latest cancer drug, which it is commercializing with global pharmaceutical giant Pfizer Key takeaways: CStone announced its monoclonal antibody drug Cejemly has been approved by China’s drug regulator for treatment of certain lung cancers The company is valued relatively low compared with its peers, and is expected by Morgan Stanley to turn a profit in 2023 By Wut Yee Biomedical company CStone Pharmaceuticals (2616.HK) has been cleared in China to sell its first cancer drug, which it is commercializing with the global pharmaceutical giant…

Read More »

I-Mab Founder Retakes Reins in Latest Shakeup Ahead of Commercialization Phase

Drug maker announces latest senior appointments as investors anticipate regulatory approval for some of its products as early as 2023 Key takeaways Four-year company veteran and CEO Joan Shen to depart I-Mab as chairman and founder Zang Jingwu gets set to resume the role Analysts upbeat as company earmarks 2023 for regulatory approval of key drugs and launch of production facility By Richard Barbarossa In a twist on an old adage, it appears to be a case of “out with the old and in with the not-so-new,” at drug developer…

Read More »

As U.S. Takes Aim at China Drug Makers, Innovators Appear at Biggest Risk

Washington’s campaign to keep cutting-edge technology out of China took a new twist late last week with the addition of Chinese medical companies to U.S. blacklists Key takeaways: Washington has blacklisted 37 medical-related companies, most of them Chinese, over concerns their skills and technology could be used to help the Chinese military Shares of companies that develop their own drugs are coming under more pressure than peers who license drugs from third-parties following the move   By Doug Young In these troubled times of U.S.-China tensions, sometimes being a copycat has…

Read More »

Skepticism Greets Rare Disease Drug Maker CANbridge in Hong Kong IPO

Company’s shares tumble 27% in trading debut a week ago, but have stabilized since then on hopes for strong growth of China’s market for drugs to treat rare diseases Key Takeaways: CANbridge Pharma’s shares lost more than a quarter of their value on their Hong Kong trading debut a week ago, but have stabilized since then Company has three drugs approved for sale, though revenue remained modest at about $1 million in first quarter of 2021 By Shirley Lau In terms of a promising future, the newly listed CANbridge Pharmaceuticals…

Read More »

Chinese Wheelchair Maker Tests U.S. Regulator’s Appetite for Controversial VIE Structure

Jin Medical is first Chinese firm using the variable interest entity (VIE) structure to apply for a New York IPO since the U.S. regulator temporarily banned such listings earlier this year Key Takeaways: Jin Medical is the first Chinese company using a VIE structure to seek a New York listing since the U.S. securities regulator temporarily banned such applications earlier this year The wheelchair maker said in its prospectus it believes its application is legally acceptable to various Chinese regulators By Doug Young When it comes to Chinese firms listing…

Read More »